Status:
COMPLETED
Occlutech Septal Occluder (Figulla Flex II) Study
Lead Sponsor:
Occlutech International AB
Conditions:
Secundum Atrial Septal Defects
Eligibility:
All Genders
Phase:
NA
Brief Summary
The objectives of the study are: * To determine the efficacy of the Figulla Flex II device compared with that of the Amplatzer ASO device for transcatheter closure of secundum atrial septal defects *...
Detailed Description
Inclusion criteria A patient will be eligible for study participation if he/she meets the following criteria: 1. Able to fluently speak and understand the language in which the study is being conduct...
Eligibility Criteria
Inclusion
- A patient will be eligible for study participation if he/she meets the following criteria:
- Able to fluently speak and understand the language in which the study is being conducted
- Has ostium secundum atrial septal defect
- Has a defect hole with a diameter of \< 38 mm
- Has a left-to-right shunt with a Qp/Qs ratio of ≥ 1.5:1 or the presence of right ventricular volume overload determined by transthoracic echo (TTE) or clinical symptoms due to the atrial septal defect
- Has a distance of \> 5 mm from the margins of the defect(s) to the coronary sinus, arterioventricular (AV) valves and right upper pulmonary vein as measured by echocardiography
- Agrees to participate in the study and comply with the follow-up schedule
- Is willing to freely give (or Legally Authorized Representative is willing to freely give) Informed Consent prior to treatment
- Willing to return for the post-treatment evaluation
Exclusion
- Has multiple defects which can't adequately be covered by the device
- Has associated congenital cardiac anomalies which require cardiac surgery
- a. Has a known sensitivity to contrast media that cannot be controlled adequately with pre-medication.
- Patient is currently participating in another clinical device or drug trial that has not completed its primary endpoint or that will clinically confound the current study endpoints or does not permit subjects to participate in other studies. Typically, subjects that are involved in the long-term surveillance phase of a clinical study are eligible.
- Has ostium primum atrial septal defects
- Has sinus venosus atrial septal defects
- Has partial anomolous pulmonary venous drainage
- Has pulmonary vascular resistance above 7 Woods units or a right-toleft shunt at the atrial level with a peripheral arterial saturation less than 94%
- Has a recent myocardial infarction, unstable angina and decompensated congestive heart failure (CHF)
- Has right and/or left ventricular decompensation with ejection fraction of \< 30%
- Has an active bacterial and/or viral infection
- Has any type of serious infection \< 1 month prior to the procedure
- Has malignancy where life expectancy is \< 2 years
- Has demonstrated intracardiac thrombi on echocardiography
- Weighs \< 8 kg
- Has gastritis, gastric ulcer, duodenal ulcer, etc. and other contraindications to aspirin therapy unless other anti-platelet agents can be administered for 6 months
- Has an unstable condition or otherwise thought to be unreliable or incapable of complying with the requirements of the clinical investigational plan (CIP).
- Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
Key Trial Info
Start Date :
May 21 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT04488120
Start Date
May 21 2012
End Date
October 1 2017
Last Update
July 27 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.